
BHVN
Healthcare · Biotechnology · $2.09B market cap
$13.82-0.25 (-1.8%)Nov 13, 4:00 PM EST
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · +188.8% over 90 days · 30-day revisions 2 up, 1 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Oct 29, 2026 | After the close | -0.80 | -0.86 | -7.5% |
| Aug 10, 2026 | After the close | -0.77 | -0.91 | -18.2% |
| May 4, 2026 | After the close | -0.76 | -0.69 | +9.2% |
| Mar 19, 2026 | Time not confirmed | -1.18 | -0.90 | +23.7% |
| Nov 10, 2025 | Before the open | -1.54 | -1.47 | +4.5% |
| Aug 11, 2025 | Before the open | -1.57 | -1.63 | -3.8% |
| May 12, 2025 | After the close | -1.47 | -1.64 | -11.6% |
| Mar 3, 2025 | Time not confirmed | -1.60 | -1.71 | -6.9% |
| Nov 12, 2024 | After the close | -1.55 | -1.74 | -12.3% |
| Aug 8, 2024 | After the close | -1.70 | -3.50 | -105.9% |
| May 9, 2024 | After the close | -1.62 | -1.77 | -9.3% |
| Feb 29, 2024 | After the close | -1.41 | -1.81 | -28.4% |
| Nov 14, 2023 | After the close | -1.34 |
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial…
| -1.50 |
| -11.9% |
| Jul 31, 2023 | Before the open | -1.19 | -1.32 | -10.9% |
| May 12, 2023 | After the close | -1.41 | -1.03 | +27.0% |
| Mar 23, 2023 | After the close | -1.22 | -3.32 | -172.1% |
| Nov 9, 2022 | Before the open | -2.41 | -1.75 | +27.4% |
| Aug 5, 2022 | Before the open | -2.58 | -6.21 | -140.7% |
| May 10, 2022 | Before the open | -2.53 | -2.97 | -17.4% |
| Feb 25, 2022 | Before the open | -2.04 | -3.01 | -47.5% |
| Nov 9, 2021 | Before the open | -2.40 | -2.63 | -9.6% |
| Aug 9, 2021 | Before the open | -2.72 | -3.23 | -18.8% |
| May 10, 2021 | Before the open | -2.82 | -4.21 | -49.3% |
| Mar 1, 2021 | Before the open | -2.97 | -3.62 | -21.9% |
| Nov 9, 2020 | Before the open | -2.89 | -3.27 | -13.1% |
| Aug 10, 2020 | Before the open | -2.61 | -3.08 | -18.0% |
| May 7, 2020 | After the close | -2.34 | -3.07 | -31.2% |
| Feb 25, 2020 | After the close | -1.87 | -2.85 | -52.4% |
| Nov 1, 2019 | After the close | -1.57 | -2.04 | -29.9% |
| Aug 8, 2019 | After the close | -1.92 | -4.67 | -143.2% |
| May 7, 2019 | Before the open | -1.48 | -1.41 | +4.7% |
| Feb 28, 2019 | After the close | -1.21 | -1.34 | -10.7% |
| Nov 13, 2018 | After the close | -1.07 | -1.53 | -43.0% |
| Aug 14, 2018 | After the close | -1.18 | -1.01 | +14.4% |
| May 15, 2018 | After the close | -1.14 | -2.32 | -103.5% |
| Mar 6, 2018 | After the close | -1.20 | -0.75 | +37.5% |